Tango Therapeutics CFO granted RSUs and options
Tango Therapeutics, Inc.’s Chief Financial Officer Matthew Gall received new equity-based compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Tango Therapeutics, Inc.’s Chief Financial Officer Matthew Gall received new equity-based compensation. He was granted 40,000 shares of Common Stock in the form of restricted stock units, which represent rights to receive an equal number of shares as they vest over time.
The RSUs vest over three years: 13,200 units on or about May 10, 2027, 13,200 on or about May 10, 2028, and 13,600 on or about May 9, 2029, subject to continued service. He was also granted stock options for 240,000 shares of Common Stock at an exercise price of $20.98 per share, vesting 25% on April 15, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, also contingent on continued service.
Insider Trade Summary
Grant/Award: 280,000 shares
Grant/Award
2 txns
Insider
Gall Matthew
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 240,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 40,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 240,000 contracts (Direct);
Common Stock — 40,000 shares (Direct)
Footnotes (2)
- F1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs shall vest over a three-year period at a rate of (i) 13,200 RSUs on or about May 10, 2027, (ii) 13,200 RSUs on or about May 10, 2028 and (iii) 13,600 RSUs on or about May 9, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
- F2. This option shall vest and become exercisable over a four-year period, at a rate of 25% on April 15, 2027 with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Key Figures
RSU grant size: 40,000 shares
Option grant size: 240,000 shares
Option exercise price: $20.98/share
+4 more
7 metrics
RSU grant size
40,000 shares
Restricted stock units representing Common Stock granted to CFO
Option grant size
240,000 shares
Stock options for Common Stock granted to CFO
Option exercise price
$20.98/share
Exercise price for 240,000 stock options
RSU vesting 2027
13,200 RSUs
Vest on or about May 10, 2027, subject to continuous service
RSU vesting 2028
13,200 RSUs
Vest on or about May 10, 2028, subject to continuous service
RSU vesting 2029
13,600 RSUs
Vest on or about May 9, 2029, subject to continuous service
Option initial vesting
25% on April 15, 2027
First tranche of option vesting, remaining monthly thereafter
Key Terms
restricted stock units, vest, Stock Option (Right to Buy), exercise price, +1 more
5 terms
restricted stock units financial
"These shares are represented by restricted stock units (the "RSUs")."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
vest financial
"The RSUs shall vest over a three-year period at a rate of..."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price": "20.9800""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
continuous service financial
"subject to the Reporting Person's continuous service with the Issuer"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Tango Therapeutics (TNGX) CFO Matthew Gall report in this Form 4?
He reported equity awards from Tango Therapeutics: 40,000 restricted stock units and stock options for 240,000 shares at an exercise price of $20.98 per share, all granted as compensation and subject to multi‑year vesting and continued service conditions.
How many Tango Therapeutics (TNGX) RSUs were granted to the CFO and how do they vest?
Matthew Gall received 40,000 restricted stock units. These RSUs vest over three years: 13,200 on or about May 10, 2027, another 13,200 on or about May 10, 2028, and 13,600 on or about May 9, 2029, assuming he remains continuously employed.
What stock options did Tango Therapeutics (TNGX) grant its CFO in this Form 4?
The CFO received stock options for 240,000 shares of Common Stock with a $20.98 per share exercise price. The options vest 25% on April 15, 2027, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service.
Are the Tango Therapeutics (TNGX) Form 4 transactions open‑market buys or compensation grants?
These transactions are compensation-related grants, not open‑market purchases or sales. Both the 40,000 RSUs and the 240,000 stock options are coded as awards (transaction code A) and vest over time, contingent on the CFO’s ongoing service.
What are the post-transaction holdings reported for Tango Therapeutics (TNGX) CFO Matthew Gall?
After these awards, the Form 4 shows 40,000 shares of Common Stock represented by RSUs and 240,000 stock options as directly held positions, each subject to their respective vesting schedules before the underlying shares can be fully accessed or exercised.
What conditions affect vesting of the Tango Therapeutics (TNGX) CFO’s new RSUs and options?
Both awards require continuous service with Tango Therapeutics through each vesting date. RSUs vest in three annual tranches through 2029, while options vest 25% in April 2027 and monthly thereafter, so leaving early could prevent unvested portions from being earned.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates